Vaccinex (VCNX) provided an update on new clinical findings from its SIGNAL-AD Phase 1b/2 trial of pepinemab antibody in Alzheimer’s disease. Vaccinex recently announced results of the phase 1b/2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback